Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework

被引：0

作者：

Bryony Langford

Alex Diamantopoulos

Toby M. Maher

Yoshikazu Inoue

Klaus B. Rohr

Michael Baldwin

机构：

[1] Symmetron Limited,Hastings Center for Pulmonary Research and Division of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine

[2] University of Southern California,Inflammation, Repair and Development Section

[3] National Heart and Lung Institute,undefined

[4] Imperial College,undefined

[5] National Hospital Organization Kinki-Chuo Chest Medical Center,undefined

[6] Boehringer Ingelheim International GmbH,undefined

来源：

Advances in Therapy | 2022年 / 39卷

关键词：

Bayesian analysis; Extrapolation; Idiopathic pulmonary fibrosis; Nintedanib; Progressive fibrosing interstitial lung disease; Survival analysis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1045 / 1054

页数：9

共 19 条

[1]

Cottin V(2019)Fibrosing interstitial lung diseases: knowns and unknowns Eur Respir Rev 28 180100-19

[2]

Kolb M(2019)The natural history of progressive fibrosing interstitial lung diseases Respir Res 20 57-249

[3]

Vašáková M(2019)Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases Eur Respir J 54 1900161-68

[4]

Wollin L(2018)Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases Eur Respir Rev 27 180076-1017

[5]

Cottin V(2021)Progressive fibrosing interstitial lung diseases: a new concept and indication of nintedanib Mod Rheumatol 31 13-583

[6]

Makino S(2018)The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype Eur Respir Rev 27 180077-188

[7]

Olson AL(2017)Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation Pham Stat 4 232-1727

[8]

Gamalo-Siebers MA-O(2019)Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON Lancet Respir Med 7 60-undefined

[9]

Crestani B(2020)The natural history of progressive fibrosing interstitial lung diseases Eur Respir J 55 2000085-undefined

[10]

Brown KK(2021)The burden of progressive fibrotic interstitial lung disease across the UK Eur Respir J 58 2100221-undefined

← 1 2 →